DESI withdrawals
Executive Summary
FDA is providing opportunities for hearings on its proposals to withdraw approval of 25 ANDAs for certain single-entity coronary vasodilator products containing isosorbide dinitrate, and for one NDA and five ANDAs for certain nitroglycerin transdermal systems. The agency is proposing to withdraw approval for the products because the sponsors failed to submit bioequivalency/bioavailability data required under the Drug Efficacy Study Implementation program. Several of the products listed in the March 22 and March 25 Federal Register notices are no longer being marketed, sponsors indicated
You may also be interested in...
Schwarz Pharma Settles False Claims Suit For $22 Million, As DoJ Continues Focus On DESI Drugs
Lawsuit alleges Schwarz failed to advise CMS that two products, including the nitroglycerin patch Deponit, did not qualify for federal reimbursement.
Deponit BE/BA Submissions Supported By FDA Guidances - Schwarz Pharma
Recent FDA guidances on bioequivalence support Schwarz Pharma's argument that it has submitted adequate BE and bioavailability data for its transdermal nitroglycerin product Deponit under the Drug Efficacy Study Implementation program, Schwarz argued in recent correspondence to FDA.
Deponit BE/BA Submissions Supported By FDA Guidances - Schwarz Pharma
Recent FDA guidances on bioequivalence support Schwarz Pharma's argument that it has submitted adequate BE and bioavailability data for its transdermal nitroglycerin product Deponit under the Drug Efficacy Study Implementation program, Schwarz argued in recent correspondence to FDA.